证券代码：301515 证券简称：港通医疗 编号：2023-001 | 投资者关系活动 | □分析师会议 □特定对象调研 | | --- | --- | | 类别 | □业绩说明会 □媒体采访 | | | □新闻发布会 □路演活动 | | | ☑现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 四川发展证券投资基金 | | 人员姓名 | 杨晨、汤英朴、刘宇翔 | | 时间 | 2023 年 12 月 5 日下午 14：30-16：30 | | 地点 | 港通医疗会议室 | | 上市公司接待人 | 董事、董事会秘书、副总经理：陈兴根 | | 员姓名 | 证券事务代表：陈丽佳 公司董事、董事会秘书、副总经理陈兴根先生陪同调研的 | | 投资者关系活动 | 投资者参观了产品展示间、生产车间等场所，并简要介绍了公 | | | 司的发展历程、主要产品、竞争优势、业务布局、2023 年前 | | | 三季度经营业绩等内容，并就投资者关注的问题进行了沟通和 | | | 交流。本次主要交流情况如下： | | 主要内容介绍 | 1、医院新增床位数对公司医用气体装备及系统的业绩增 | | | ...

2023 年 10 月 27 日 四川港通医疗设备集团股份有限公司（以下简称"公司"）沉痛公告，公 司董事、副总经理樊雄然先生近日在出差期间因急病不幸逝世，公司及公司董 事会对樊雄然先生的逝世致以沉痛哀悼，并向其家人致以深切慰问。 樊雄然先生担任公司董事、副总经理期间恪尽职守、勤勉尽责，忠实履行 了作为董事、高级管理人员应尽的职责和义务，为公司的发展做出了重要贡献， 公司及公司董事会谨此表示衷心感谢。 根据《公司法》的规定，樊雄然先生逝世未导致公司董事会成员低于法定 最低人数，不会影响公司董事会的正常运行。 特此公告。 四川港通医疗设备集团股份有限公司董事会 证券代码：301515 证券简称：港通医疗 公告编号：2023-015 四川港通医疗设备集团股份有限公司 关于公司董事、副总经理去世的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 ...

Financial Performance - Revenue for Q3 2023 was CNY 90,410,826.27, a decrease of 21.60% compared to the same period last year[4] - Net profit attributable to shareholders was CNY -4,496,245.51, a decline of 173.77% year-on-year[4] - Total operating revenue for Q3 2023 reached CNY 434,178,245.95, an increase of 16.5% compared to CNY 372,618,308.28 in Q3 2022[21] - Net profit for Q3 2023 was CNY 37,812,558.09, up 38.2% from CNY 27,394,181.77 in the same period last year[22] - Operating profit for the period was CNY 45,451,920.20, representing a 50.2% increase from CNY 30,278,037.02 in Q3 2022[21] - The basic and diluted earnings per share for Q3 2023 were both CNY 0.38, slightly up from CNY 0.37 in Q3 2022[22] - The total comprehensive income for Q3 2023 was CNY 37,538,433.00, compared to CNY 26,476,423.98 in the previous year[22] Cash Flow and Liquidity - Cash flow from operating activities showed a net outflow of CNY -145,974,594.11, a significant decrease of 1504.40% compared to the previous year[10] - Cash flow from operating activities was CNY 484,436,006.10, compared to CNY 456,009,793.81 in the same quarter last year[24] - The net cash flow from operating activities was -145,974,594.11 CNY, a decrease from 10,394,065.97 CNY in the previous year[25] - Total cash inflow from financing activities reached 871,113,207.55 CNY, compared to 141,000,000.00 CNY in the same period last year[25] - The net cash flow from financing activities was 706,317,532.40 CNY, significantly higher than 40,193,232.30 CNY in the previous year[25] - The net increase in cash and cash equivalents was 576,525,136.69 CNY, up from 45,723,725.07 CNY year-over-year[26] - The ending balance of cash and cash equivalents was 695,890,822.93 CNY, compared to 130,036,324.13 CNY at the end of the same quarter last year[26] - Total cash outflow from operating activities was 642,902,686.80 CNY, an increase from 483,845,822.83 CNY in the previous year[25] - Cash paid to employees was 108,357,327.22 CNY, up from 72,220,055.38 CNY year-over-year[25] - Cash paid for taxes was 40,661,811.99 CNY, compared to 25,798,259.17 CNY in the same period last year[25] - Cash inflow from investment activities was 41,016,077.64 CNY, a significant increase from 3,188.30 CNY in the previous year[25] - The net cash flow from investment activities was 16,161,020.90 CNY, compared to -4,929,068.72 CNY in the same period last year[25] Assets and Liabilities - Total assets increased to CNY 1,901,910,947.11, representing a growth of 63.69% from the end of the previous year[4] - As of September 30, 2023, the total assets of Sichuan Porton Medical Equipment Group Co., Ltd. reached CNY 1,901,881,647.11, an increase from CNY 1,161,890,043.02 at the beginning of the year[18] - The company's current assets amounted to CNY 1,737,972,934.40, up from CNY 994,152,464.46 at the start of the year, indicating a significant growth in liquidity[19] - Total liabilities increased to CNY 618,133,675.13, compared to CNY 607,453,544.91 at the end of Q3 2022[20] - The company's total equity rose to CNY 1,283,777,271.98, significantly up from CNY 554,436,498.11 in the previous year[20] - The total equity attributable to shareholders increased by 131.55% to CNY 1,283,777,271.98[4] Research and Development - Research and development expenses rose to CNY 22,210,409.11, an increase of 47.51% compared to the same period last year[10] - Research and development expenses for Q3 2023 were CNY 22,210,409.11, an increase of 47.5% from CNY 15,056,780.47 in Q3 2022[21] Stock and Shareholder Information - The company plans to issue 25 million shares, increasing its registered capital from CNY 75 million to CNY 100 million[16] - The company is set to lift restrictions on 76,291,486 shares by July 2024, which may impact stock liquidity[15] - The company reported a total of 76,291,486 restricted shares, with significant portions held by major shareholders[14] Market Strategy - The company is actively pursuing market expansion and new product development strategies to enhance its competitive position in the medical equipment sector[15]

证券代码：301515 证券简称：港通医疗 公告编号：2023-013 四川港通医疗设备集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称为"公司"）分别于2023年8 月11日、2023年8月30日召开第四届董事会第九次会议、2023年第二次临时股东 大会，审议通过《关于变更注册资本、公司类型及修订<公司章程>并办理工商 变更登记的议案》,具体内容详见公司于巨潮资讯网（http://www.cninfo.com.cn） 披露的相关公告。 公司已于近日完成上述工商变更登记和《公司章程》备案手续，并取得了成 都市市场监督管理局换发的《营业执照》，现将相关情况公告如下： 一、新取得《营业执照》的基本信息 1. 公司名称：四川港通医疗设备集团股份有限公司 2. 统一社会信用代码：91510100206881448P 3. 类型：股份有限公司（台港澳与境内合资、上市） 5. 经营范围：设计、制造、安装、销售：医用气体系统、医院洁净手术部 净化系统、医院物流系统、医用呼叫 ...

北京金杜（成都）律师事务所 关于四川港通医疗设备集团股份有限公司 2023 年第二次临时股东大会之法律意见书 致：四川港通医疗设备集团股份有限公司 北京金杜（成都）律师事务所（以下简称本所）接受四川港通医疗设备集团股 份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员 会《上市公司股东大会规则（2022 年修订）》（以下简称《股东大会规则》）等中华 人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规 章和规范性文件和现行有效的公司章程有关规定，指派律师出席公司于 2023 年 8 月 30 日召开的 2023 年第二次临时股东大会（以下简称本次股东大会），并对本次 股东大会的相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1． 经公司 2021 年第二次临时股东大会审议通过的《四川港通医疗设备集团 股份有限公司章程（草案）》（以下简称《公司章程》）； 2． 公司 ...

证券代码：301515 证券简称：港通医疗 公告编号：2023-012 四川港通医疗设备集团股份有限公司 2023年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会无出现否决提案的情形。 1.会议召集人：四川港通医疗设备集团股份有限公司（以下简称"公司"） 董事会； 2.会议主持人：公司董事长陈永先生； 3.现场会议召开时间：2023年8月30日（星期三）下午14:00； 4.现场会议召开地点：四川省成都市简阳市凯力威工业大道南段356号公司 会议室； 5.网络投票时间： 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为2023年8月30 日的交易时间，即9:15-9:25，9:30—11:30和13:00—15:00； （2）通过深圳证券交易所互联网投票系统进行网络投票的开始时间为2023 年8月30日上午9:15，结束时间为2023年8月30日下午15:00。 6.召开方式：现场会议与网络投票相结 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 343,767,419.68, representing a 33.61% increase compared to CNY 257,298,550.29 in the same period last year[25]. - Net profit attributable to shareholders reached CNY 42,308,803.60, a significant increase of 98.64% from CNY 21,299,324.53 year-on-year[25]. - The basic earnings per share doubled to CNY 0.56, compared to CNY 0.28 in the previous year[25]. - The total assets of the company increased by 8.56% to CNY 1,261,358,260.92 from CNY 1,161,890,043.02 at the end of the previous year[25]. - The net assets attributable to shareholders rose by 7.79% to CNY 597,653,074.34 from CNY 554,436,498.11 at the end of the previous year[25]. - The net cash flow from operating activities was negative at CNY -62,506,054.72, worsening by 14.08% compared to CNY -54,791,381.20 in the same period last year[25]. - Non-recurring gains and losses amounted to CNY 16,923,340.35 after tax, primarily from the disposal of non-current assets and government subsidies[29]. - The company achieved a weighted average return on equity of 7.35%, up from 4.31% in the previous year[25]. - The net profit excluding non-recurring items was CNY 25,385,463.25, reflecting a 26.89% increase from CNY 20,006,324.72 year-on-year[25]. Regulatory Compliance and Transparency - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the review of the half-year report[4]. - The report indicates that the company is focused on maintaining compliance with regulatory requirements set by the China Securities Regulatory Commission[14]. - The company is committed to transparency, with all relevant documents available for public inspection at the securities department office[11]. - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance and reflect the company's financial position as of June 30, 2023[183]. - The company has assessed its ability to continue as a going concern for the next 12 months and found no issues affecting this capability[181]. Research and Development - The company emphasizes R&D with a dedicated technical center responsible for product development, standard setting, and addressing technical challenges[48]. - The R&D team consists of highly qualified professionals across multiple disciplines, ensuring a strong foundation for innovation[49]. - The company has established a comprehensive R&D management mechanism, optimizing resource allocation to enhance product development and technological innovation capabilities[51]. - The company actively engages in technology cooperation with universities and research institutions to stay updated on industry advancements and foster innovation[52]. - The company plans to upgrade its R&D center and increase funding for technological innovation and product development[53]. Market and Product Development - The company continues to focus on expanding its market presence and enhancing its product offerings in the medical equipment sector[20]. - The company focuses on the research and development of medical gas equipment and systems, as well as clean medical equipment and systems, providing integrated solutions for various medical institutions[36]. - The medical gas equipment and systems market is experiencing rapid growth due to increasing healthcare demands and government policies promoting high-quality hospital development[34]. - The company is focusing on expanding its product line, including new oxygen systems with an oxygen concentration range of 90%-96% (ml/ml) expected to be launched by April 2028[58]. - The company is actively involved in the development of new medical air compression systems for hospitals, with updates expected by November 2023[58]. - The company has plans for market expansion, particularly in the areas of ICU and CCU equipment, to meet the growing demand for mechanical ventilation[58]. Risk Management - The company has outlined risks and countermeasures in the report, specifically in the section discussing risks faced by the company[4]. - The company faces risks from intensified market competition in the medical gas equipment and systems sector, which may affect its market position[91]. - To mitigate risks, the company plans to enhance R&D investment and improve product lines to strengthen its core competitiveness[92]. - The company has established a comprehensive safety production management system to address safety production risks associated with manufacturing and project construction[93]. - The company is at risk of bad debts due to increasing accounts receivable from public hospitals, which are primarily funded by government allocations[94]. - Fluctuations in raw material prices, such as stainless steel and copper, may adversely impact the company's gross margin and profit levels[95]. - The company plans to diversify procurement channels to reduce reliance on any single supplier or market, aiming to mitigate the impact of raw material price fluctuations[96]. Shareholder Information - The company reported a plan not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[5]. - The largest shareholder, Chen Yong, holds 37.03% of the shares, amounting to 27,774,000 shares[135]. - Foreign institutional investors hold 15.33% of the shares, equivalent to 11,500,000 shares[135]. - The total number of ordinary shareholders at the end of the reporting period is 41[135]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[138]. Operational Efficiency - The company operates primarily through project-based management, with a focus on bidding for contracts, ensuring compliance with national standards and project requirements during implementation[43]. - After project delivery, the company conducts regular inspections and maintenance, leveraging the Kangtong Cloud Monitoring Platform for remote monitoring and timely maintenance of medical equipment[44]. - The company maintains a stable business model with no significant changes expected in the near future, driven by its product structure and industry dynamics[47]. - The company has a strong project implementation team, ensuring quality control through self-managed core processes during project installations[65]. - The company offers integrated solutions from planning and design to project implementation and operation maintenance, enhancing its competitive edge[60]. Financial Position - Total assets increased to CNY 1,261,358,260.92 as of June 30, 2023, up from CNY 1,161,890,043.02 at the beginning of the year, representing a growth of approximately 8.6%[148]. - Current assets totaled CNY 1,101,671,227.45, an increase of 10.9% from CNY 994,152,464.46 at the start of the year[147]. - Accounts receivable rose to CNY 616,903,373.34, up 7.1% from CNY 576,281,023.75[147]. - Inventory increased significantly to CNY 263,990,655.48, a rise of 24.6% compared to CNY 211,837,827.15[147]. - Total liabilities reached CNY 663,705,186.58, an increase of 9.3% from CNY 607,453,544.91[149].

2023年半年度公司控股股东及其他关联方资金占用、公司对外担保情况的 专项说明和独立意见 经核查，报告期内，公司控股股东及其他关联方不存在占用公司资金 的情形，亦不存在以前期间发生并延续到报告期内的控股股东、实际控制 人及其他关联方占用公司资金的情况；公司不存在为控股股东、实际控制 人及其他关联方、非法人单位或个人提供担保的情形，也无以前期间发生 延续至报告期的违规对外担保事项。 四川港通医疗设备集团股份有限公司独立董事 关于控股股东及其他关联方占用公司资金、公司对外担保情况的 专项说明和独立意见 根据《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》《上市公司独立董事规则》等相关规定，我们作为四川港通医疗设备集 团股份有限公司（以下简称"公司"）的独立董事，基于独立判断的立场，仔细 阅读相关材料，并对公司2023年半年度控股股东及其他关联方占用公司资金、公 司对外担保情况进行了认真核查，现发表专项说明和独立意见如下： 独立董事：黄永庆、杜云波、陈启明 2023 年 8 月 25 日 ...

四川港通医疗设备集团股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 法定代表人： 陈永 主管会计工作负责人： 张秋 会计机构负责人：李春 非经营性资金占用 资金占用方 名称 占用方与上市 公司的关联关 系 上市公司核算的 会计科目 2023 年期初 占用资金余额 2023 年半年度占 用累计发生金额 （不含利息） 2023 年半年度 占用资金的利息 （如有） 2023 年半年度 偿还累计发生 金额 2023 年半年度 期末占用资金 余额 占用形成 原因 占用性质 控股股东、实际控制人及 其附属企业 非经营性占用 非经营性占用 小计 - - - - 前控股股东、实际控制人 及其附属企业 非经营性占用 非经营性占用 小计 - - - - 其他关联方及附属企业 非经营性占用 小计 总计 - - - - 其它关联资金往来 资金往来方 名称 往来方与上市 公司的关联关 系 上市公司核算的 会计科目 2023 年期初 往来资金余额 2023 年半年度往 来累计发生金额 （不含利息） 2023 年半年度 往来资金的利息 （如有） 2023 年半年度 偿还累计发生 金额 2023 年 ...

中信建投证券股份有限公司 关于对四川港通医疗设备集团股份有限公司 持续督导的培训报告 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》 等相关规定，保荐机构于 2023 年 8 月 3 日对四川港通医疗设备集团股份 有限公司（以下称"港通医疗"、"公司"）参与培训的公司实际控制人、 董事、监事及高级管理人员等相关人员进行了专门培训，并对参与培训的 相关人员派发了培训资料，督促其认真学习培训内容，本次培训的具体情 况如下： 一、培训时间 2023 年 8 月 3 日。 二、培训地点 通过线上及现场结合的方式进行培训，现场培训地点为四川省成都市 简阳市凯力威工业大道南段 356 号港通医疗会议室。 三、培训内容 本次培训内容为上市公司信息披露及规范运作相关事项，本次培训重 点结合法律法规及相关案例，从上市公司信息披露、上市公司治理、关联 交易、资金占用、对外担保、内幕交易等方面进行了讲解。通过此次培训， 公司实际控制人、董事、监事及高级管理人员等相关人员加深了对中国证 券监督管理委员会和深圳证券交易所相关法律、法规、相关业务规则的了 解和认识，加强理解作为上市公司管理人员在信息披露、上市公司治理 ...